Associations between UGT1A1*6/*28 polymorphisms and irinotecan-induced severe toxicity in Chinese gastric or esophageal cancer patients

FOLFIRIChemotherapy in Patients with Advanced Non Resectable Esophageal or Junctional Adenocarcinoma: A Pilot Study

(2014) C. Ferte et al.   JOURNAL OF CHEMOTHERAPY

Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer

(2013) Lucía Cortejoso et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

UGT1A1*6/*28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients

(2013) Jing Gao et al.   MEDICAL ONCOLOGY

The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimens

(2012) Ali Osman Kaya et al.   JOURNAL OF CHEMOTHERAPY

A genotype-directed phase I–IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer

(2011) E Marcuello et al.   BRITISH JOURNAL OF CANCER

Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients

(2011) Katerina Shulman et al.   CANCER

Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms

(2011) Taroh Satoh et al.   CANCER SCIENCE

Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results

(2010) S. R. Park et al.   ANNALS OF ONCOLOGY

UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy

(2010) E Martinez-Balibrea et al.   BRITISH JOURNAL OF CANCER

UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer

(2010) Yu Sunakawa et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Randomized Phase II Trial of Paclitaxel Plus Carboplatin Therapy Versus Irinotecan Plus Cisplatin Therapy as First-Line Chemotherapy for Clear Cell Adenocarcinoma of the Ovary

(2010) Satoshi Takakura et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer

(2010) B Glimelius et al.   PHARMACOGENOMICS JOURNAL

Clinical Significance of UDP-Glucuronosyltransferase 1A1*6 for Toxicities of Combination Chemotherapy with Irinotecan and Cisplatin in Gynecologic Cancers

(2009) Masashi Takano et al.   ONCOLOGY

Phase I study of combination chemotherapy with irinotecan hydrochloride and nedaplatin for cervical squamous cell carcinoma: Japanese gynecologic oncology group study

(2009) Yamamoto   ONCOLOGY REPORTS

UGT1A1*28genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan

(2009) Roberta Ferraldeschi et al.   PHARMACOGENOMICS

UGT1A1 gene polymorphism: Impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer

(2009) Christoph Schulz et al.   WORLD JOURNAL OF GASTROENTEROLOGY

UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma

(2008) Chun-Yu Liu et al.   CANCER